据华尔街日报，在数月的关税威胁与更严定价规则压力下，多位制药企业CEO走进白宫，宣布药价协议，以换取监管宽松。但对礼来(LLY.US)和诺和诺德(NVO.US)而言，其考量截然不同。这笔交易不只是简单的“停火”，更是买到了市场扩张的通行证。通过下调Wegovy和Zepbound等药品价格，他们换来了医保对肥胖症治疗的覆盖——这意味着数以百万计的新患者。他们“以价换量”筑起了市场护城河：后来者将无法再复制早期GLP-1减肥药高价上市的模式。对辉瑞等竞争者来说，这意味着必须进入一个利润更薄、制造成本极高的市场。该协议的核心是医保，虽然细节尚不清晰，但总体逻辑明确：药企提供药品净价折扣，政府扩大老年人的报销范围。乍看之下，折扣幅度相当可观。礼来和诺和诺德将以每月245美元的价格在联邦医疗保险下提供GLP-1药物，患者最早自2026年4月起仅需支付50美元的共付费用。这比此前动辄上千美元的标价低得多。而作为交换，两家公司可将覆盖人群几乎翻倍。伯恩斯坦估算，这项医保协议打开约3,000万人的新市场，年销售潜力达270亿美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.